Utilization of Antihypertensive Agents during 1 Year
| Characteristic | HCTZ (n = 18,713) | Amlodipine (n = 11,520) | Lisinopril (n = 21,138) | Valsartan (n = 9314) | Overall (n = 60,685) |
|---|---|---|---|---|---|
| Persistence, % | 55.8* | 60.3* | 64.8* | 69.4* | 61.9 |
| Discontinuation, % | 44.2* | 39.7* | 35.2* | 30.6* | 38.1 |
| Length of therapy, days | 265.8* | 277.8* | 282.0* | 298.7* | 278.8 |
| [Mean (95% CI)] | (264.2–267.3) | (175.8–279.7) | (280.7–283.4) | (297.1–300.4) | (277.9–279.6) |
| Time to discontinuation, days† | 116.2* | 141.6* | 141.9* | 177.5* | 137.0 |
| [Mean (95% CI)] | (113.9–118.6) | (138.3–144.9) | (139.4–144.4) | (173.4–181.5) | (135.6–138.5) |
| MPR, adjusted % | 73.2‡ | 78.3‡ | 84.7‡ | 89.5‡ | 81.6 |
| (95% CI) | (72.7–73.6) | (77.7–79.0) | (84.3–85.2) | (88.8–90.2) | (81.3–81.9) |
| Adherence, adjusted % | 78.6‡ | 85.2‡ | 89.9‡ | 90.1‡ | 86.2 |
| (95% CI) | (77.9–79.4) | (84.3–86.1) | (89.3–90.6) | (89.0–91.1) | (85.8–86.6) |
* P ≤ .001 between groups (one-way analysis of variance with Bonferroni post-hoc for multiple comparisons or χ2 as appropriate).
† Computed for subjects discontinuing therapy.
‡ Overall model statistically significant at P ≤ .001; adjustment included baseline age, gender, year of initial prescription, and Charlson comorbidity score.
HCTZ, hydrochlorothiazide; CI, confidence interval; MPR, medication possession ratio.